The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer

References

• Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10:415-27; PMID:14760060; http://dx.doi.org/10.1158/1078-0432.CCR-0642-03
   PubMed Web of Science ®Google Scholar
• Cai SX. Small molecule vascular disrupting agents: Potential new drugs for cancer treatment. Recent Pat Anticancer Drug Discov 2007; 2:79-101; PMID:18221055; http://dx.doi.org/10.2174/157489207779561462
   PubMed Web of Science ®Google Scholar
• Kremmidiotis G, Leske AF, Lavranos TC, Beaumont D, Gasic J, Hall A, O'Callaghan M, Matthews CA, Flynn B. BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. Mol Cancer Ther 2010; 9:1562-73; PMID:20515948; http://dx.doi.org/10.1158/1535-7163.MCT-09-0815
   PubMed Web of Science ®Google Scholar
• Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003; 21:4428-38; PMID:14645433; http://dx.doi.org/10.1200/JCO.2003.12.986
   PubMed Web of Science ®Google Scholar
• Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies Cancer Res 2006; 66:11520-39.; PMID:17178843; http://dx.doi.org/10.1158/0008-5472.CAN-06-2848
   PubMed Web of Science ®Google Scholar
• Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5:423-35; PMID:15928673; http://dx.doi.org/10.1038/nrc1628
   PubMed Web of Science ®Google Scholar
• Iversen AB1, Busk M, Horsman MR Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy. Acta Oncol. 2013; 52:1320-6; PMID:23988183; http://dx.doi.org/10.3109/0284186X.2013.825050
   PubMed Web of Science ®Google Scholar
• Yeung SC, She M, Yang H, Pan J, Sun L, Chaplin D. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model.J Clin Endocrinol Metab 2007; 92:2902-9.; PMID:17550961; http://dx.doi.org/10.1210/jc.2007-0027
   PubMed Web of Science ®Google Scholar
• Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, Ledermann J, Shreeves G, Poupard L, Lu SP, Balkissoon J, et al. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 2011; 22:2036-41; PMID:21273348; http://dx.doi.org/10.1093/annonc/mdq708
   PubMed Web of Science ®Google Scholar
• Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, et al. Phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent Vadimezan (ASA404) in advanced non–small-cell lung cancer. J Clin Oncol 2011; 29:2965-71; PMID:21709202; http://dx.doi.org/10.1200/JCO.2011.35.0660
   PubMed Web of Science ®Google Scholar
• Siemann DW, Shi W. Dual targeting of tumor vasculature: Combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer res 2008; 28:2027-31; PMID:18751370
   PubMed Web of Science ®Google Scholar
• Rischin D, Bibby DC, Chong G, Kremmidiotis G, Leske AF, Matthews CA, Wong SS, Rosen MA, Desai J. Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation. Clin Cancer res 2011; 17:5152-60; PMID:21690571; http://dx.doi.org/10.1158/1078-0432.CCR-11-0937
   PubMed Web of Science ®Google Scholar
• Nowak AK, Brown C, Millward MJ, Creaney J, Byrne MJ, Hughes B, Kremmidiotis G, Bibby DC, Leske AF, Mitchell PL, et al. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer 2013; 81:422-7; PMID:23787063; http://dx.doi.org/10.1016/j.lungcan.2013.05.006
   PubMed Web of Science ®Google Scholar
• Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Müller M, Wood J, Martiny-Baron G, Unger C, Marmé D. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 2000;60:4819-24.; PMID:10987292
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-24; PMID:17215529; http://dx.doi.org/10.1056/NEJMoa065044
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28:1061-8; PMID:20100962; http://dx.doi.org/10.1200/JCO.2009.23.9764
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:3584-90; PMID:19487381; http://dx.doi.org/10.1200/JCO.2008.20.1293
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369:722-31; PMID:23964934; http://dx.doi.org/10.1056/NEJMoa1303989
   PubMed Web of Science ®Google Scholar
• Spear MA, LoRusso P, Mita A, Mita M. Vascular disrupting agents (VDA) in oncology: Advancing towards new therapeutic paradigms in the clinic. Curr Drug Targets 2011; 12:2009-15; PMID:21777190; http://dx.doi.org/10.2174/138945011798829366
   PubMed Web of Science ®Google Scholar
• Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marmé D, Lorusso PM. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005; 11:416-20.; PMID:15701823
   PubMed Web of Science ®Google Scholar
• Nathan P, Zweifel M, Padhani AR, Koh DM, Ng M, Collins DJ, Harris A, Carden C, Smythe J, Fisher N, et al. Phase I trial of Combretastatin A4 Phosphate (CA4P) in combination with Bevacizumab in patients with advanced cancer. Clin Cancer Res 2012; 18:3428-39; PMID:22645052; http://dx.doi.org/10.1158/1078-0432.CCR-11-3376
   PubMed Web of Science ®Google Scholar
• Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11:393-410.; PMID:21606941; http://dx.doi.org/10.1038/nrc3064
   PubMed Web of Science ®Google Scholar
• Ke Q, Costa. Hypoxia-Inducible Factor-1 (HIF-1). Mol Pharmacol 2006; 70:1469-80; PMID:16887934; http://dx.doi.org/10.1124/mol.106.027029
   PubMed Web of Science ®Google Scholar
• Shinojima T, Oya M, Takayanagi A, Mizuno R, Shimizu N, Murai M. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. Carcinogenesis 2007; 28:529-36; PMID:16920734; http://dx.doi.org/10.1093/carcin/bgl143
   PubMed Web of Science ®Google Scholar
• Lin Z, Weinberg JM, Malhotra R, Merritt SE, Holzman LB, Brosius FC 3rd. GLUT-1 reduces hypoxia-induced apoptosis and JNK pathway activation. J Physiol Endocrinol Metab 2000; 278:E958-66
   PubMed Web of Science ®Google Scholar
• Kazemi S, Mounir Z, Baltzis D, Raven JF, Wang S, Krishnamoorthy JL, Pluquet O, Pelletier J, Koromilas AE. A novel function of eIF2alpha kinases as inducers of the phosphoinositide-3 kinase signaling pathway. Mol Biol Cell 2007; 18:3635-44; PMID:17596516; http://dx.doi.org/10.1091/mbc.E07-01-0053
   PubMed Web of Science ®Google Scholar
• Ellis L, Shah, Hammers H, Lehet K, Sotomayer P, Azabdaftari G, Seshadri M, Pili R. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. Mol Cancer Ther 2012; 11:383-92; PMID:22084164; http://dx.doi.org/10.1158/1535-7163.MCT-11-0748
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, et al. RECORD-1 study group. Phase 3 trial of Everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010; 116:4256-65; PMID:20549832; http://dx.doi.org/10.1002/cncr.25219
   PubMed Web of Science ®Google Scholar
• Flynn BL, Gill GS, Grobelny DW, Chaplin JH, Paul D, Leske AF, Lavranos TC, Chalmers DK, Charman SA, Kostewicz E et al. Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties. J Med Chem 2011; 54:6014-27; PMID:21774499; http://dx.doi.org/10.1021/jm200454y
   PubMed Web of Science ®Google Scholar
• Trotter MJ, Olive PL, Chaplin DJ. Effect of vascular marker Hoechst 33342 on tumour perfusion and cardiovascular function in the mouse. Br J Cancer 1990; 62:903-8; PMID:2257217; http://dx.doi.org/10.1038/bjc.1990.406
   PubMed Web of Science ®Google Scholar
• Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, Kálai T, Hideg K, Kuppusamy P. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition. Cancer Biol Ther 2011; 12:837-45; PMID:21885917; http://dx.doi.org/10.4161/cbt.12.9.17713
   PubMed Web of Science ®Google Scholar